Section Edited by Ignacio Melero, MD, PhD and Alexandra Snyder Charen, MD
This section focuses on the discovery, development and/or clinical significance of biomarkers for immunomodulatory anti-cancer treatments. This includes biomarkers for diagnostic, prognostic, predictive and pharmacodynamic purposes measured using diverse strategies including, but not limited to, genomic or gene expression,serological analyses, cell-based or single-cell studies, in situ/localized tissue-based protein imaging, high content/multiparametric molecular platforms and imaging studies conducted in model systems, retrospective collections and clinical trials.This section also welcomes studies reporting novel methods, technologies or computational approaches to interrogate the anti-tumor immune response that have the potential to advance the field. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty. Special emphasis is assigned to: 1) Rigorous analytical validation of assays used (e.g. antibodies, mRNA probes, DNA sequences, molecular biosensors and modified reagents); 2) Reproducibility of findings in multiple populations/datasets/models; and 3) Use of appropriate statistics to account for cases stratification (e.g. cut-point selection), data overfitting and multiple hypothesis testing (e.g. adjustment of significance thresholds, P-values or other strategies to reduce type I error).
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancerPraful Ravi, Dory Freeman, Jonathan Thomas, Arvind Ravi, Charlene Mantia, Bradley A McGregor, Jacob E Berchuck, Ilana Epstein, Petra Budde, Behnaz Ahangarian Abhari, Elena Rupieper, Jana Gajewski, Ann-Sophie Schubert, Annika L Kilian, Manuel BräutigamSee the full list of authors
2 February 2024
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PETJohanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van Oordt, Idris Bahce
1 February 2024
Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancerMengting Gao, Xueying Wu, Xi Jiao, Ying Hu, Yanni Wang, Na Zhuo, Fengxiao Dong, Yujiao Wang, Fengyuan Wang, Yanshuo Cao, Chang Liu, Jian Li, Lin Shen, Henghui Zhang, Zhihao Lu
1 February 2024
Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapyZhiqiang Mo, Ling Lv, Qicong Mai, Qiao Li, Jian He, Tao Zhang, Jingwu Xu, Jiayan Fang, Ning Shi, Qing Gou, Xiaoming Chen, Jing Zhang, Wenhang Zhuang, Haosheng Jin
30 January 2024
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumabMara Serena Serafini, Stefano Cavalieri, Lisa Licitra, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Marco Merlano, Federica Perrone, Andrea Vingiani, Nerina Denaro, Francesco PerriSee the full list of authors
30 January 2024
Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinomaFeng Zhang, Wenfeng Liu, Fansheng Meng, Qiuyu Jiang, Wenqing Tang, Zhiyong Liu, Xiahui Lin, Ruyi Xue, Si Zhang, Ling Dong
25 January 2024
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4 naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanomaMagdalena Kovacsovics-Bankowski, Johanna M Sweere, Connor P Healy, Natalia Sigal, Li-Chun Cheng, William D Chronister, Shane A Evans, John Marsiglio, Berit Gibson, Umang Swami, Alyssa Erickson-Wayman, Jordan P McPherson, Yoko S Derose, Annaleah Larson Eliason, Carlos O MedinaSee the full list of authors
17 January 2024
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancerGulfem D Guler, Yuhong Ning, Ceyda Coruh, Giuliana P Mognol, Tierney Phillips, Maryam Nabiyouni, Kyle Hazen, Aaron Scott, Wayne Volkmuth, Samuel Levy
11 January 2024
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapyShixiang Wang, Yi Xiong, Yihao Zhang, Haitao Wang, Minjun Chen, Jianfeng Li, Peng Luo, Yung-Hung Luo, Markus Hecht, Benjamin Frey, Udo Gaipl, Xuejun Li, Qi Zhao, Hu Ma, Jian-Guo Zhou
11 January 2024
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang, Fang-Shu Ou, Federico Innocenti, Shannon M Mumenthaler, Priya Jayachandran, Natsuko Kawanishi, Annika Lenz, Shivani Soni, Sandra AlgazeSee the full list of authors
11 January 2024